Clare Arnott's Publications

About Clare Arnott's Publications

Co-Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial

    Diabetes, Obesity and Metabolism Date published:

  • Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Secondary Analysis of the Salt Substitute and Stroke Study (SSaSS): Effects of Potassium-Enriched Salt on Cardiac Outcomes

    Hypertension Date published:

  • Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD

    Clinical Journal of the American Society of Nephrology Date published:

  • Prediction of new-onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS

    Diabetes, Obesity and Metabolism Date published:

  • Knowledge, attitudes, and behaviors related to dietary salt intake and the acceptability of salt substitute among the Australian culturally and linguistically diverse community: An online survey

    The Journal of Clinical Hypertension Date published:

  • Effects of iron on cardiovascular, kidney and safety outcomes in patients with chronic kidney disease: a systematic review and meta-analysis

    Unknown Date published:

  • Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

    Journal of the American Heart Association Date published:

  • Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

    Circulation Date published:

  • The Effect of Weight Loss Through Lifestyle Interventions in Patients With Heart Failure With Preserved Ejection Fraction-A Systematic Review and Meta-Analysis of Randomised Controlled Trials

    Heart, Lung and Circulation Date published:

  • Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial

    Kidney International Reports Date published:

  • Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial

    International Journal of Cardiology Date published:

  • A life-course approach to tackling noncommunicable diseases in women

    Nature Medicine Date published:

  • Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

    Journal of the American Society of Nephrology Date published:

  • Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes

    Kidney International Date published: